drugset / Trial / NCT02612155

A Multi-site Study of Autologous Cord Blood Cells for Hypoxic Ischemic Encephalopathy

NCT02612155 ↗

Phase 2 Completed 35 enrolled Michael Cotten The Robertson Foundation · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will test the safety and efficacy of an infusion of a baby's own (autologous) umbilical cord blood as compared with placebo in babies born with history and signs of hypoxic-ischemic brain injury.

Timeline

Start
2017-03-30
Primary completion
2019-08-05
Completion
2019-08-05

Outcome

Missed primary endpoint

registry analysis (other test); Intervention Cell Recipients vs Placebo Recipients; p = 0.06; Fisher Exact NCT02612155 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject autologous nucleated cord blood cells Cell therapy — Intravenous

Indications